CELU
Companies
NASDAQ
Celularity Inc.
Health Care
$1.74
-$0.29 (-13.94%)
Price Chart
Overview
About CELU
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.
Market Cap
$70.8M
Volume
204.1K
Avg. Volume
114.2K
P/E Ratio
-3.6870174
Dividend Yield
0.00%
Employees
225.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.80
Moderate Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, CELU shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$70.8M
Volume204.1K
P/E Ratio-3.69
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
July 29, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025